statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ikena Oncology, Inc. (NASDAQ:IKNA - Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 1,120,000...

Ikena Oncology, Inc. (NASDAQ:IKNA) Sees Large Increase in Short Interest

HC Wainwright restated their buy rating on shares of Ikena Oncology (NASDAQ:IKNA  Free Report) in a research report report published on Tuesday, Benzinga reports. The brokerage currently has...

HC Wainwright Reaffirms Buy Rating for Ikena Oncology (NASDAQ:IKNA)

Ikena Oncology (NASDAQ:IKNA  Get Free Report)s stock had its buy rating reiterated by HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They...

Ikena Oncology (NASDAQ:IKNA) Earns Buy Rating from HC Wainwright

Latest Ratings for IKNA
 DateFirmActionFromTo Dec 2021HC Wainwright & Co.Initiates Coverage OnBuy Aug 2021Credit SuisseMaintainsOutperform Apr 2021JefferiesInitiates Coverage OnBuy
 View More...

The Analyst Landscape: 4 Takes On Ikena Oncology

Ikena Oncology, Inc. (NASDAQ:IKNA  Free Report)  Investment analysts at William Blair cut their Q1 2024 EPS estimates for Ikena Oncology in a research report issued on Tuesday, March...

Q1 2024 EPS Estimates for Ikena Oncology, Inc. (NASDAQ:IKNA) Lowered by Analyst

Ikena Oncology (NASDAQ:IKNA  Get Free Report)s stock had its outperform rating reissued by Wedbush in a research note issued to investors on Tuesday, RTT News reports...

Ikena Oncology (NASDAQ:IKNA) Given "Outperform" Rating at Wedbush

IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in...

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena, Company ), a targeted oncology company forging new territory in patient-directed cancer treatment, today...

Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference

Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise Dr. Germa will drive clinical development...

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Ikena Oncology (NASDAQ:IKNA  Get Free Report)s stock had its outperform rating reaffirmed by equities researchers at Wedbush in a research note issued to investors on...

Ikena Oncology (NASDAQ:IKNA) Rating Reiterated by Wedbush

Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412, and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.

Volume	46,032.00
52-Wk High	$7.64
52-Wk Low	$1.02

IKNA Ikena Oncology Inc

About

Feed

News

Sentiment

Earnings

Fundamentals